In a challenging fundraising environment for venture capital, Hatteras Venture Partners successfully secured $200 million for two new funds targeting seed- and early-stage biotech companies. This capital influx stands out amid the broader slowdown in biotech investment activity, signaling continued investor interest in emerging life sciences startups. Additional recent financing developments further shape the investment landscape for innovative biotech ventures.